aTyr Pharma (NASDAQ:ATYR) Releases Earnings Results, Beats Estimates By $0.05 EPS

aTyr Pharma (NASDAQ:ATYR) posted its quarterly earnings data on Friday. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05, FiscalAI reports.

aTyr Pharma Trading Down 10.0%

ATYR traded down $0.06 during trading on Friday, hitting $0.50. 3,510,665 shares of the company’s stock were exchanged, compared to its average volume of 1,909,190. aTyr Pharma has a 1 year low of $0.40 and a 1 year high of $7.29. The stock has a 50 day moving average price of $0.82 and a 200 day moving average price of $0.81. The firm has a market cap of $49.42 million, a P/E ratio of -0.64 and a beta of 0.66.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on ATYR shares. Jefferies Financial Group reissued a “buy” rating on shares of aTyr Pharma in a research report on Friday, March 6th. Wall Street Zen lowered shares of aTyr Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, aTyr Pharma has an average rating of “Hold” and a consensus target price of $25.67.

Institutional Investors Weigh In On aTyr Pharma

Institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System purchased a new stake in aTyr Pharma during the second quarter worth approximately $28,000. Legal & General Group Plc acquired a new position in shares of aTyr Pharma during the second quarter worth about $49,000. Prudential Financial Inc. purchased a new stake in shares of aTyr Pharma in the second quarter worth about $63,000. Oxford Asset Management LLP purchased a new stake in shares of aTyr Pharma in the second quarter worth about $70,000. Finally, Creative Planning purchased a new stake in shares of aTyr Pharma in the second quarter worth about $74,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.